Jeffrey C. Hanselman

2.9k citations

38 papers · 2.2k indexed · 2 hit papers · h-index 19

Surgery top 2%
Molecular Biology top 10%
Endocrinology, Diabetes and Metabolism top 2%
Cancer Research top 5%
Cardiology and Cardiovascular Medicine top 10%

Co-authors: Roger S. Newton Lawrence A. LeiterXin ZhaoChristie M. Ballantyne Clay T. Cramer Diane MacDougall Stephen L. Pinkosky С. И. Филиппов
Topics: Lipoproteins and Cardiovascular Health (23 papers)Diabetes, Cardiovascular Risks, and Lipoproteins (8 papers)Cancer, Lipids, and Metabolism (7 papers)
Cited by: Endocrinology, Diabetes and Metabolism Surgery Cancer Research
Journals: JAMA CirculationSHILAP Revista de lepidopterología
Partner nations: United States Canada United Kingdom

In The Last Decade

Jeffrey C. Hanselman

36 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease

2019 324 citations Anne C. Goldberg, Lawrence A. Leiter et al. profile →
Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study

2018 294 citations Christie M. Ballantyne, Maciej Banach et al. Atherosclerosis profile →

Peers

Countries citing papers authored by Jeffrey C. Hanselman

Since Specialization

Citations

This map shows the geographic impact of Jeffrey C. Hanselman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey C. Hanselman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey C. Hanselman more than expected).

Fields of papers citing papers by Jeffrey C. Hanselman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey C. Hanselman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey C. Hanselman. The network helps show where Jeffrey C. Hanselman may publish in the future.

Co-authorship network of co-authors of Jeffrey C. Hanselman

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey C. Hanselman. A scholar is included among the top collaborators of Jeffrey C. Hanselman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey C. Hanselman. Jeffrey C. Hanselman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Evaluation of the efficacy and safety of bempedoic acid in women and men: Pooled analyses from phase 3 trials 2023 ·Atherosclerosis ·Anne C. Goldberg,Maciej Banach,Alberico L. Catapano,P. Barton Duell,Lawrence A. Leiter,Jeffrey C. Hanselman,Lei Lei,G.B. John Mancini	5
2	Bempedoic acid in patients with type 2 diabetes mellitus, prediabetes, and normoglycaemia: A post hoc analysis of efficacy and glycaemic control using pooled data from phase 3 clinical trials 2022 ·Diabetes Obesity and Metabolism ·Lawrence A. Leiter,Maciej Banach,Alberico L. Catapano,P. Barton Duell,Antonio M. Gotto,Ulrich Laufs,G.B. John Mancini,Kausik K. Ray,Jeffrey C. Hanselman,Zhan Ye,Harold Bays	41
3	Effect of bempedoic acid plus ezetimibe fixed-dose combination vs ezetimibe or placebo on low-density lipoprotein cholesterol in patients with type 2 diabetes and hypercholesterolemia not treated with statins 2021 ·SHILAP Revista de lepidopterología ·Harold Bays,Seth J. Baum,Eliot A. Brinton,Jorge Plutzky,Jeffrey C. Hanselman,R. Teng,Christie M. Ballantyne	12
4	Abstract 11417: Bempedoic Acid and Glycemic Control: A Pooled Analysis of 4 Phase 3 Clinical Trials 2019 ·Circulation ·Lawrence A. Leiter,Maciej Banach,Alberico L. Catapano,P. Barton Duell,Antonio M. Gotto,Ulrich Laufs,G.B.John Mancini,Kausik K. Ray,Jeffrey C. Hanselman,Zhan Ye,Harold Bays	2
5	Complementary low-density lipoprotein-cholesterol lowering and pharmacokinetics of adding bempedoic acid (ETC-1002) to high-dose atorvastatin background therapy in hypercholesterolemic patients: A randomized placebo-controlled trial 2019 ·Journal of clinical lipidology ·Narendra D. Lalwani,Jeffrey C. Hanselman,Diane MacDougall,Lulu Ren Sterling,Clay T. Cramer	55
6	Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled studybreakdown → 2018 ·Atherosclerosis ·Christie M. Ballantyne,Maciej Banach,G.B. John Mancini,Norman E. Lepor,Jeffrey C. Hanselman,Xin Zhao,Lawrence A. Leiter	294
7	Effect of ETC-1002 on Serum Low-Density Lipoprotein Cholesterol in Hypercholesterolemic Patients Receiving Statin Therapy 2016 ·The American Journal of Cardiology ·Christie M. Ballantyne,James M. McKenney,Diane MacDougall,Janice R. Margulies,Paula Robinson,Jeffrey C. Hanselman,Narendra D. Lalwani	94
8	Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance 2016 ·Journal of clinical lipidology ·Paul D. Thompson,Diane MacDougall,Roger S. Newton,Janice R. Margulies,Jeffrey C. Hanselman,David G. Orloff,James M. McKenney,Christie M. Ballantyne	118
9	ETC-1002 LOWERS LDL-C MORE THAN EZETIMIBE IN PATIENTS WITH HYPERCHOLESTEROLEMIA WITH OR WITHOUT STATIN INTOLERANCE AND HAS A SIMILAR SAFETY AND TOLERABILITY PROFILE 2015 ·Journal of the American College of Cardiology ·Paul D. Thompson,Christie M. Ballantyne,James McKenney,David G. Orloff,Diane MacDougall,Janice R. Margulies,Jeffrey C. Hanselman,Roger S. Newton	5
10	Efficacy and Safety of ETC-1002, a Novel Investigational Low-Density Lipoprotein-Cholesterol–Lowering Therapy for the Treatment of Patients With Hypercholesterolemia and Type 2 Diabetes Mellitus 2014 ·Arteriosclerosis Thrombosis and Vascular Biology ·María J. Gutiérrez,(unknown),Diane MacDougall,Jeffrey C. Hanselman,Janice R. Margulies,Poul Strange,Mark A. Milad,Scott McBride,Roger S. Newton	135
11	AMP-activated protein kinase: an emerging drug target to regulate imbalances in lipid and carbohydrate metabolism to treat cardio-metabolic diseases 2012 ·Journal of Lipid Research ·Rai Ajit K. Srivastava,Stephen L. Pinkosky,С. И. Филиппов,Jeffrey C. Hanselman,Clay T. Cramer,Roger S. Newton	240
12	AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism 2012 ·Journal of Lipid Research ·Stephen L. Pinkosky,С. И. Филиппов,Rahul Srivastava,Jeffrey C. Hanselman,(unknown),Timothy R. Hurley,Clay T. Cramer,Mark A. Spahr,(unknown),Jacob L. Houghton,Chris Baker,Mark Naples,Khosrow Adeli,Roger S. Newton	191
13	Atherosclerosis in Octodon degus (degu) as a model for human disease 2010 ·Atherosclerosis ·Reynold Homan,Jeffrey C. Hanselman,(unknown),(unknown),Patrick A. Lester,(unknown),Stephen L. Pinkosky,Christine K. Castle,Bruce Taylor	19
14	Hepatoselectivity of statins: Design and synthesis of 4-sulfamoyl pyrroles as HMG-CoA reductase inhibitors 2007 ·Bioorganic & Medicinal Chemistry Letters ·William K.C. Park,Robert M. Kennedy,Scott D. Larsen,Steve Miller,Bruce D. Roth,Yuntao Song,Bruce A. Steinbaugh,(unknown),Bradley D. Tait,Mark C. Kowala,Bharat K. Trivedi,Bruce J. Auerbach,(unknown),(unknown),Jeffrey C. Hanselman,Zhiwu Lin,Gina H. Lu,Andrew Robertson,Catherine Sekerke	45
15	Design and synthesis of novel, conformationally restricted HMG-CoA reductase inhibitors 2007 ·Bioorganic & Medicinal Chemistry Letters ·Jeffrey A. Pfefferkorn,Chulho Choi,Yuntao Song,Bharat K. Trivedi,Scott D. Larsen,(unknown),(unknown),Jeffrey C. Hanselman,Zhiwu Lin,Gina H. Lu,Andrew Robertson,Catherine Sekerke,Bruce J. Auerbach,A.G. Pavlovsky,Melissa S. Harris,Graeme Bainbridge,Nicole Caspers	30
16	Pyrazole inhibitors of HMG-CoA reductase: An attempt to dramatically reduce synthetic complexity through minimal analog re-design 2007 ·Bioorganic & Medicinal Chemistry Letters ·Scott D. Larsen,(unknown),Kevin J. Filipski,Jeffrey T. Kohrt,Jeffrey A. Pfefferkorn,Roderick J. Sorenson,Bradley D. Tait,(unknown),(unknown),Jeffrey C. Hanselman,Gina H. Lu,Andrew Robertson,Catherine Sekerke,Mark C. Kowala,Bruce J. Auerbach	11
17	Discovery of pyrrole-based hepatoselective ligands as potent inhibitors of HMG-CoA reductase 2007 ·Bioorganic & Medicinal Chemistry ·(unknown),Bruce J. Auerbach,Chulho Choi,(unknown),Jeffrey C. Hanselman,Scott D. Larsen,Gina H. Lu,Karl Olsen,Jeffrey A. Pfefferkorn,Andrew Robertson,Catherine Sekerke,Bharat K. Trivedi,Paul C. Unangst	25
18	Modulation of lipoprotein metabolism by inhibition of sphingomyelin synthesis in ApoE knockout mice 2006 ·Atherosclerosis ·Tae‐Sik Park,Robert L. Panek,Mark D. Rekhter,Sandra Bak Mueller,Wendy S. Rosebury,Andrew Robertson,Jeffrey C. Hanselman,Erick Kindt,Reynold Homan,Sotirios K. Karathanasis	85
19	Expression of the mRNA encoding truncated PPARα does not correlate with hepatic insensitivity to peroxisome proliferators 2001 ·Molecular and Cellular Biochemistry ·Jeffrey C. Hanselman,(unknown),(unknown),(unknown),Arnold D. Essenburg,Thomas J. Rea,Charles L. Bisgaier,(unknown)	19
20	Elevated hepatic apolipoprotein A-I transcription is associated with diet-induced hyperalphalipoproteinemia in rabbits 2000 ·Life Sciences ·(unknown),Thomas J. Rea,Jeffrey C. Hanselman,Charles L. Bisgaier,Brian R. Krause,Michael E. Pape	6

About Jeffrey C. Hanselman

Jeffrey C. Hanselman is a scholar working on Surgery, Endocrinology, Diabetes and Metabolism and Cancer Research, having authored 38 papers that have together received 2.2k indexed citations. Recurring topics across this work include Lipoproteins and Cardiovascular Health (23 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (8 papers) and Cancer, Lipids, and Metabolism (7 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (607 citations), Surgery (1.3k citations) and Cancer Research (410 citations). Jeffrey C. Hanselman has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include Roger S. Newton, Lawrence A. Leiter, Xin Zhao, Christie M. Ballantyne, Clay T. Cramer, Diane MacDougall, Stephen L. Pinkosky, С. И. Филиппов, Narendra D. Lalwani and G.B. John Mancini. Their work appears in journals such as JAMA, Circulation and SHILAP Revista de lepidopterología.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact